Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients

Bibliographic Details
Title: Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
Authors: Francesca Romana Spinelli, Arbi Pecani, Francesco Ciciarello, Tania Colasanti, Manuela Di Franco, Francesca Miranda, Fabrizio Conti, Guido Valesini, Cristiano Alessandri
Source: BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-9 (2017)
Publisher Information: BMC, 2017.
Publication Year: 2017
Collection: LCC:Diseases of the musculoskeletal system
Subject Terms: Diseases of the musculoskeletal system, RC925-935
More Details: Abstract Background Rheumatoid arthritis (RA) patients carry a high risk of cardiovascular morbidity and mortality. The excess of cardiovascular disease cannot be entirely explained by traditional risk factors and the immune system contributes to the development of atherosclerosis. Moreover, post-translational modifications such as citrullination and carbamylation have been linked to inflammation and atherosclerosis. Anti-carbamylated proteins antibodies (anti-CarP) are a new subset of autoantibodies identified in RA patients. This study aimed to investigate a possible association between anti-CarP and subclinical atherosclerosis in RA patients. Methods We enrolled RA patients and normal healthy controls (NHS) without known cardiovascular risk factors or heart disease. Cardiovascular risk was assessed using the Modified Systemic Coronary Risk Evaluation (mSCORE). Anti-CarP were investigated by a solid phase “home-made” ELISA. Anti-citrullinated protein antibodies (ACPA) and Rheumatoid Factor (RF) were investigated by ELISA assays. Subclinical atherosclerosis was evaluated by brachial artery Flow-Mediated Dilatation (FMD) and Carotid Intima-Media Thickness (c-IMT) while arterial stiffness by Ankle-Brachial Index (ABI) and Cardio-Ankle Vascular Index (CAVI). Results We enrolled 50 RA patients (34 F and 16 M, mean age 58.4 ± 13.1 years, mean disease duration 127 ± 96.7 months) and 30 age and sex matched NHS. According to the mSCORE, 58% of patients had a low risk, 32% a moderate and 8% a high risk for cardiovascular disease. FMD was significantly lower in RA patients than in NHS (5.6 ± 3.2 vs 10.7 ± 8.1%; p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1471-2474
Relation: http://link.springer.com/article/10.1186/s12891-017-1563-8; https://doaj.org/toc/1471-2474
DOI: 10.1186/s12891-017-1563-8
Access URL: https://doaj.org/article/0434428984614eeebb8d633cf34985af
Accession Number: edsdoj.0434428984614eeebb8d633cf34985af
Database: Directory of Open Access Journals
More Details
ISSN:14712474
DOI:10.1186/s12891-017-1563-8
Published in:BMC Musculoskeletal Disorders
Language:English